Stocklytics Platform
Asset logo for symbol BRKR
Bruker
BRKR61
$70.44arrow_drop_up4.74%$3.19
Asset logo for symbol BRKR
BRKR61

$70.44

arrow_drop_up4.74%

Performance History

Chart placeholder
Key Stats
Open$68.24
Prev. Close$67.25
EPS2.39
Next Earnings DateDec 16, 2024
LOWHIGH
Day Range67.96
70.86
52 Week Range53.79
94.86
Ratios
EPS2.39

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Bruker (BRKR)

Founded in 1963, Bruker Corp (BRKR) is a leading global provider of scientific instruments and solutions for molecular and materials research. With a strong presence in over 100 countries, the company delivers innovative technologies that enable scientists and researchers to explore and understand the world around us. Bruker Corp offers a diverse portfolio of products, including analytical and diagnostic instruments, life science tools, and industrial solutions. These cutting-edge instruments are used in a wide range of applications, from drug discovery and development to environmental analysis and quality control. The company's commitment to innovation and customer satisfaction has earned it a strong reputation in the scientific community. With a market capitalization of over $10 billion, Bruker Corp is a leader in its industry and continues to drive growth and innovation.
Despite the challenges posed by the COVID-19 pandemic, Bruker Corp has maintained its strong financial performance. In its most recent quarterly report, the company reported revenue of $599 million, representing a 9% increase compared to the same period last year. This growth can be attributed to strong demand for the company's life science and materials research instruments. The company's net income also saw a significant increase, reaching $73 million, a 32% increase year-over-year. Bruker Corp has a solid balance sheet and a healthy cash flow, allowing it to invest in research and development to drive further innovation. The company consistently allocates a significant portion of its revenue to R&D, demonstrating its commitment to staying at the forefront of scientific advancements. With a PEG ratio of 2.31, Bruker Corp is considered undervalued compared to its industry peers, presenting a potential opportunity for investors. The company's stock price has also shown resilience in the face of market volatility, with the 52-week range of BRKR being $42.45 to $86.27. The stock is currently trading near the upper end of this range, indicating positive investor sentiment. Bruker Corp has a strong trading volume, indicating active investor interest and liquidity in the stock. Overall, the company's financial performance, market capitalization, and position within the industry make it an attractive investment option for those interested in the scientific instruments sector.
Sector
Healthcare
Industry
Medical Devices
CEO
Dr. Frank H. Laukien Ph.D.
Headquarters
Billerica
Employees
8525
Exchange
NASDAQ
add Bruker to watchlist

Keep an eye on Bruker

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Bruker's (BRKR) price per share?

The current price per share for Bruker (BRKR) is $70.44. The stock has seen a price change of $3.19 recently, indicating a 4.74% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Bruker (BRKR)?

For Bruker (BRKR), the 52-week high is $94.86, which is 34.67% from the current price. The 52-week low is $53.79, the current price is 30.95% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Bruker (BRKR) a growth stock?

Bruker (BRKR) has shown an average price growth of 0.41% over the past three years. It has received a score of 69 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Bruker as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Bruker (BRKR) stock price performance year to date (YTD)?

As of the latest data, Bruker (BRKR) has a year-to-date price change of -2.57%. Over the past month, the stock has experienced a price change of 10.23%. Over the last three months, the change has been 8.49%. Over the past six months, the figure is -24.32%. Looking at a longer horizon, the five-year price change stands at 62.79%.
help

Is Bruker (BRKR) a profitable company?

Bruker (BRKR) has a net income of $427.2M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 51.17% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 10.08% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.96B, with a revenue growth rate of 17.14%, providing insight into the company's sales performance and growth. The gross profit is $1.52B. Operating income is noted at $482.3M. Furthermore, the EBITDA is $555.5M.
help

What is the market capitalization of Bruker (BRKR)?

Bruker (BRKR) has a market capitalization of $10.34B. The average daily trading volume is 1.36M, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media